His extensive experience includes fostering strategic partnerships, implementing customer-focused programs, and growing complex businesses. Tremaine brings over 26 years of experience within the life sciences and CRO industry. In his new role, Tremaine will oversee commercial operations with an emphasis on collaboration and relentless dedication to clients' success.
According to the company, this unique approach builds on the expertise gained through its standard-of-care business, Acutis Diagnostics, which has processed over three million patient samples over the past seven years with turnaround times that have been consistently at the top of the industry. Acutis Biosciences combines a multi-omics biomarker profiling approach with data integration to provide pharmaceutical and biotechnology companies with tools needed to help advance clinical discovery. The company also appointed Troy Tremaine as its Chief Commercial Officer. 06.21.23Īcutis Biosciences, a biomarker discovery provider, opened a state-of-the-art 60,000-square-foot facility in Monmouth Junction, NJ. Troy Tremaine brings more than 26 years of experience within the life sciences and CRO industry. This assay is to be ordered under the guidelines issued by CDC and various departments of health to identify the presence of the virus in symptomatic patients who have tested negative for other respiratory viruses.Acutis Biosciences Opens New Facility, Names New CCO The Acutis SARS-CoV-2 test is a multiplex assay that targets three key genes-ORF1ab, N, and E, that scientists believe are key to accurately identifying the presence of the virus in patient samples. We are thankful to our development partners who have worked diligently along with our scientists, not only in providing some of the key validation material but also in ensuring us that they will be able to keep up with the demand that we have been seeing nationwide." This process, whereby we performed prescribed validation steps using various sample types, provided us with a deeper understanding of the assay than we might have experienced otherwise. "While offering an assay based on an EUA obtained by a diagnostic manufacturer rather pursuing our own might have been simpler, our team felt that by using our skill set honed in the design of our other molecular assays, it would allow us to provide the most effective solution to our clients. "We are very proud of our outstanding research and development team who have worked tirelessly on this validation," commented Jibreel Sarij, CEO. The assay will use a standard nasopharyngeal specimen from which Acutis will extract viral RNA and then test for the presence of key genes that can be used to identify its presence.
The assay will be available beginning Monday, Maand will be run under an Emergency Use Authorization granted to Acutis from the FDA. EAST NORTHPORT, N.Y., Ma/PRNewswire-PRWeb/ - Acutis Diagnostics, a clinical diagnostics laboratory headquartered in New York, announced today that it has released a multiplex laboratory test for the detection of SARS-CoV-2, the causative agent of COVID-19.
0 kommentar(er)
